Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 223 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Composite Biomarkers

Post-HSCT Monitoring - 35.0 months
ADSI
Elevated
62.6/100
Autonomic Dysfunction | stable (30-day trend)
Autonomic Dysfunction Severity Index. Higher = more dysfunction.
GVHD Score
28.0/100
Wearable Activity | stable (30-day trend)
Composite from HRV, HR, sleep fragmentation, temperature. Ring-derived, not clinical diagnosis.
Recovery
81.6/100
Trajectory Index | stable (30-day trend)
Overall recovery trajectory. Higher = better.
Pharma
1.7Z
Ruxolitinib Response | improving (30-day trend)
Pharmacodynamic response to ruxolitinib. Z-score relative to pre-treatment baseline.
CV Risk
Elevated
55.9/100
Cardiovascular Composite | stable (30-day trend)
Cardiovascular risk proxy from resting HR, HRV, SpO2. Not equivalent to Framingham or SCORE2.
Allostatic
1.1/7
Load Score | stable (30-day trend)
Cumulative physiological stress burden. Scale 0-7.
REPORT SECTION

Summary

Post-HSCT Patient | 35.0 months post-HSCT | Ruxolitinib from 2026-03-16

BiomarkerValueTrend
ADSI62.6/100stable (30-day trend)
GVHD_SCORE28.0/100stable (30-day trend)
RECOVERY_INDEX81.6/100stable (30-day trend)
CV_RISK55.9/100stable (30-day trend)
ALLOSTATIC_LOAD1.1/7stable (30-day trend)
HRV (RMSSD)
Significant
158.9% change
p=0.0000, d=1.82 (large)
Lowest HR
Significant
-20.5% change
p=0.0000, d=2.18 (large)
Average HR
Significant
-18.2% change
p=0.0000, d=2.07 (large)
Sleep Efficiency
Significant
5.6% change
p=0.0000, d=0.84 (large)
MetricPre-Rux (mean±SD)Post-Rux (mean±SD)Changep-valueCohen's dEffect
HRV (RMSSD)10.0 ± 2.5 ms25.8 ± 9.8 ms+158.9%0.00001.82large
Lowest HR76.7 ± 5.7 bpm61.0 ± 7.6 bpm-20.5%0.00002.18large
Average HR85.2 ± 6.8 bpm69.7 ± 7.6 bpm-18.2%0.00002.07large
Sleep Efficiency78.6 ± 3.4 %83.0 ± 5.7 %+5.6%0.00000.84large

Three-Period Trajectory

Pre-acute (2026-02-09) → Post-acute/Pre-Rux → Post-Rux (2026-03-16)

HRV (RMSSD): 8.6 ms → 11.2 ms → 25.8 ms (acute event = inflection, Rux stabilized)
Lowest HR: 79.6 bpm → 74.1 bpm → 61.0 bpm (steady improvement)
Average HR: 88.7 bpm → 82.0 bpm → 69.7 bpm (steady improvement)
Sleep Efficiency: 78.1 % → 79.1 % → 83.0 %

Clinical note: The composite ADSI score dilutes these individual metric signals. While ADSI aggregates multiple domains into a single index, individual metrics like HRV and heart rate show statistically significant pre/post differences that the composite score may obscure through averaging.

REPORT SECTION

Biomarker Dashboard